Riyadh : Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceuticals company announced today a partnership with Leosons Overseas Corporation, a consumer health company based in the United States through an Exclusive Licensing and Distribution agreement to manufacture and commercialize Leosons products in the MENA region.
Through this agreement, Tabuk will have the right to register, manufacture, and commercialize a range of 14 brands in several countries in the MENA region. This include several products including Jointflex®, NICE®, Leolyte®, Fiberall®, CHOOZ®, Gas-Aid®, Leona’s Vitamins®, and Clear Mist®.
This agreement grants Tabuk an immediate take over for Leosons existing business in more than 10 markets with future expansion plans to include new markets and products, and supported by Tabuk’s strong presence in the MENA region to provide consumers with solutions that will enhance health and wellbeing.
Mohammed AlHaqbani , President of Astra Industrial Group commented: “ It has been an exciting year for Tabuk and partnering with a key player in consumer health as Leosons demonstrates the importance of such segment which continues to grow at a blistering pace. We aim to continue and build on the existing business of Leosons in the region especially with our objective to localize key products at Tabuk sites”
Wisam Alkhatib , Vice President of Strategy and Business Development at Tabuk Pharmaceuticals commented: “At Tabuk Pharmaceuticals, we are excited to partner with Leosons, one of the leading players in the consumer health sector. We are confident that this agreement will strengthen our market leading position and support our strategic objective to further expand our business in KSA and the MENA region. We consider this partnership a step forward towards augmenting our plans for long-term growth and strengthening Tabuk’s over the counter business with direct contact with patients”.
John L. Ohanian , President of Leosons commented : “Leosons Overseas has demonstrated a sustained commitment to expansion where the business is widespread over 6 continents with 200 products sold to 30 plus countries yet our focus has remained the MENA region, therefore we believe our partnership with Tabuk Pharmaceuticals is transformational especially in Saudi Arabia.”
Leo Ohanian , Managing Director of Leosons, commented: “We are very pleased to establish a partnership with Tabuk Pharmaceuticals for the MENA markets. As the largest private Saudi Pharmaceutical company, Tabuk is an ideal partner to commercialize and lead our key brands in the MENA markets. With this partnership, we look forward to further strengthening our current business and be able to expand into new categories and new markets”
-Ends-
About Tabuk Pharmaceuticals:
Tabuk Pharmaceuticals Manufacturing Company is a leading Saudi pharmaceuticals company with a strong regional presence in the Middle East and North Africa (MENA). Tabuk Pharmaceuticals develops, manufactures, markets and distributes branded generic pharmaceutical products. The company also manufactures high-quality pharmaceutical products for renowned international brands and partners at its plants in Saudi Arabia. Tabuk Pharmaceuticals is a major player in the industry not only in the Kingdom, but also in MENA region. With more than 2,400 employees and four state-of-the-art plants in Tabuk and Dammam in Saudi Arabia, in addition to sites in Sudan and Algeria, Tabuk aims to serve its customers in 17 countries in MENA region, with an optimistic plans for future expansion in the region.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
